Angiotensin-(1-7) decreases skeletal muscle atrophy induced by angiotensin II through a Mas receptor-dependent mechanism

Clinical Science

Volumn 128, Issue 5, 2015, Pages 307-319

  Cisternas, Franco ^a   Morales, María Gabriela ^a   Meneses, Carla ^a   Simon, Felipe ^a,b   Brandan, Enrique ^c   Abrigo, Johanna ^a   Vazquez, Yaneisi ^a   Cabello Verrugio, Claudio ^a  

^a UNIVERSIDAD ANDRÉS BELLO   (Chile)

^b Pontificia Universidad Católica de Chile   (Chile)

^c PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

Angiotensin (1 7); Atrophy; Mas; Muscle wasting; Skeletal muscle

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; ANGIOTENSIN II; ANGIOTENSIN[1-7]; ATROGIN 1; G PROTEIN COUPLED RECEPTOR; MAS RECEPTOR; MUSCLE RING FINGER 1 PROTEIN; MYOSIN HEAVY CHAIN; PROTEIN KINASE B; UNCLASSIFIED DRUG; ANGIOTENSIN I; ANGIOTENSIN I (1-7); FBXO32 PROTEIN, MOUSE; MUSCLE PROTEIN; ONCOPROTEIN; PEPTIDE FRAGMENT; PROTO-ONCOGENE PROTEINS C-MAS-1; TRIM63 PROTEIN, MOUSE; UBIQUITIN PROTEIN LIGASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GASTROCNEMIUS MUSCLE; MALE; MOUSE; MUSCLE ATROPHY; MUSCLE CELL; MUSCLE STRENGTH; MYOTUBE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; ANIMAL; C57BL MOUSE; CELL LINE; DRUG EFFECTS; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHOSPHORYLATION;

ANGIOTENSIN I; ANGIOTENSIN II; ANIMALS; CELL LINE; GENE EXPRESSION REGULATION; MALE; MICE, INBRED C57BL; MUSCLE FIBERS, SKELETAL; MUSCLE PROTEINS; MUSCLE STRENGTH; MUSCLE, SKELETAL; MUSCULAR ATROPHY; MYOSIN HEAVY CHAINS; PEPTIDE FRAGMENTS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; SKP CULLIN F-BOX PROTEIN LIGASES; UBIQUITIN-PROTEIN LIGASES;

EID: 84922395149     PISSN: 01435221     EISSN: 14708736     Source Type: Journal    
DOI: 10.1042/CS20140215     Document Type: Article

References (66)

1. Lokireddy, S., Mouly, V., Butler-Browne, G., Gluckman, P. D., Sharma, M., Kambadur, R. and McFarlane, C. (2011) Myostatin promotes the wasting of human myoblast cultures through promoting ubiquitin-proteasome pathway-mediated loss of sarcomeric proteins. Am. J. Physiol. Cell Physiol. 301, C1316-C1324
2. Kackstein, K., Teren, A., Matsumoto, Y., Mangner, N., Mobius-Winkler, S., Linke, A., Schuler, G., Punkt, K. and Adams, V. (2012) Impact of angiotensin II on skeletal muscle metabolism and function in mice: Contribution of IGF-1, Sirtuin-1 and PGC-1alpha. Acta Histochem. 115, 363-370
3. Brecher, P. (1996) Angiotensin II and cardiac fibrosis. Trends Cardiovasc. Med. 6, 193-198
4. Agarwal, R. (2003) Proinflammatory effects of oxidative stress in chronic kidney disease: role of additional angiotensin II blockade. Am. J. Physiol. Renal. Physiol. 284, F863-F869
5. Agarwal, R., Campbell, R. C. and Warnock, D. G. (2004) Oxidative stress in hypertension and chronic kidney disease: role of angiotensin II. Semin. Nephrol. 24, 101-114
6. Antoniu, S. A. (2008) Targeting the angiotensin pathway in idiopathic pulmonary fibrosis. Expert Opin. Ther. Targets 12, 1587-1590
7. Mancini, G. B. and Khalil, N. (2005) Angiotensin II type 1 receptor blocker inhibits pulmonary injury. Clin. Invest. Med. 28, 118-126
8. Cabello-Verrugio, C., Morales, M. G., Cabrera, D., Vio, C. P. and Brandan, E. (2012) Angiotensin II receptor type 1 blockade decreases CTGF/CCN2-mediated damage and fibrosis in normal and dystrophic skeletal muscles. J. Cell. Mol. Med. 16, 752-764
9. Cabello-Verrugio, C., Acuna, M. J., Morales, M. G., Becerra, A., Simon, F. and Brandan, E. (2011) Fibrotic response induced by angiotensin-II requires NAD(P)H oxidase-induced reactive oxygen species (ROS) in skeletal muscle cells. Biochem. Biophys. Res. Commun. 410, 665-670
10. Henriksen, E. J. and Prasannarong, M. (2012) The role of the renin-angiotensin system in the development of insulin resistance in skeletal muscle. Mol. Cell. Endocrinol. 378, 15-22
11. Brink, M., Wellen, J. and Delafontaine, P. (1996) Angiotensin II causes weight loss and decreases circulating insulin-like growth factor I in rats through a pressor-independent mechanism. J. Clin. Invest. 97, 2509-2516
12. Brink, M., Price, S. R., Chrast, J., Bailey, J. L., Anwar, A., Mitch, W. E. and Delafontaine, P. (2001) Angiotensin II induces skeletal muscle wasting through enhanced protein degradation and down-regulates autocrine insulin-like growth factor I. Endocrinology 142, 1489-1496
13. Sanders, P. M., Russell, S. T. and Tisdale, M. J. (2005) Angiotensin II directly induces muscle protein catabolism through the ubiquitin-proteasome proteolytic pathway and may play a role in cancer cachexia. Br. J. Cancer 93, 425-434
14. Russell, S. T., Wyke, S. M. and Tisdale, M. J. (2006) Mechanism of induction of muscle protein degradation by angiotensin II. Cell. Signal. 18, 1087-1096
15. Russell, S. T., Eley, H. and Tisdale, M. J. (2007) Role of reactive oxygen species in protein degradation in murine myotubes induced by proteolysis-inducing factor and angiotensin II. Cell Signal. 19, 1797-1806
16. Rezk, B. M., Yoshida, T., Semprun-Prieto, L., Higashi, Y., Sukhanov, S. and Delafontaine, P. (2012) Angiotensin II infusion induces marked diaphragmatic skeletal muscle atrophy. PLoS One 7, e30276
17. Gumucio, J. P. and Mendias, C. L. (2013) Atrogin-1, MuRF-1, and sarcopenia. Endocrine 43, 12-21
18. Gomes, M. D., Lecker, S. H., Jagoe, R. T., Navon, A. and Goldberg, A. L. (2001) Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc. Natl. Acad. Sci. U.S.A. 98, 14440-14445
19. Glass, D. J. (2003) Molecular mechanisms modulating muscle mass. Trends Mol. Med. 9, 344-350
20. Foletta, V. C., White, L. J., Larsen, A. E., Leger, B. and Russell, A. P. (2011) The role and regulation of MAFbx/atrogin-1 and MuRF1 in skeletal muscle atrophy. Pflugers Arch. 461, 325-335
21. Bodine, S. C., Latres, E., Baumhueter, S., Lai, V. K., Nunez, L., Clarke, B. A., Poueymirou, W. T., Panaro, F. J., Na, E., Dharmarajan, K. et al. (2001) Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 294, 1704-1708
22. Semprun-Prieto, L. C., Sukhanov, S., Yoshida, T., Rezk, B. M., Gonzalez-Villalobos, R. A., Vaughn, C., Michael Tabony, A. and Delafontaine, P. (2011) Angiotensin II induced catabolic effect and muscle atrophy are redox dependent. Biochem. Biophys. Res. Commun. 409, 217-221
23. Bodine, S. C., Stitt, T. N., Gonzalez, M., Kline, W. O., Stover, G. L., Bauerlein, R., Zlotchenko, E., Scrimgeour, A., Lawrence, J. C., Glass, D. J. and Yancopoulos, G. D. (2001) Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat. Cell Biol. 3, 1014-1019
24. Stitt, T. N., Drujan, D., Clarke, B. A., Panaro, F., Timofeyva, Y., Kline, W. O., Gonzalez, M., Yancopoulos, G. D. and Glass, D. J. (2004) The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol. Cell 14, 395-403
25. Rommel, C., Bodine, S. C., Clarke, B. A., Rossman, R., Nunez, L., Stitt, T. N., Yancopoulos, G. D. and Glass, D. J. (2001) Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat. Cell Biol. 3, 1009-1013
26. Yoshida, T., Semprun-Prieto, L., Sukhanov, S. and Delafontaine, P. (2010) IGF-1 prevents ANG II-induced skeletal muscle atrophy via Akt- and Foxo-dependent inhibition of the ubiquitin ligase atrogin-1 expression. Am. J. Physiol. Heart Circ. Physiol. 298, H1565-H1570
27. Bonaldo, P. and Sandri, M. (2013) Cellular and molecular mechanisms of muscle atrophy. Dis. Model. Mech. 6, 25-39
28. Tallant, E. A., Ferrario, C. M. and Gallagher, P. E. (2005) Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the mas receptor. Am. J. Physiol. Heart Circ. Physiol. 289, H1560-H1566
29. Iwata, M., Cowling, R. T., Gurantz, D., Moore, C., Zhang, S., Yuan, J. X. and Greenberg, B. H. (2005) Angiotensin-(1-7) binds to specific receptors on cardiac fibroblasts to initiate antifibrotic and antitrophic effects. Am. J. Physiol. Heart Circ. Physiol. 289, H2356-H2363
30. Marangoni, R. A., Carmona, A. K., Passaglia, R. C., Nigro, D., Fortes, Z. B. and de Carvalho, M. H. (2006) Role of the kallikrein-kinin system in Ang-(1-7)-induced vasodilation in mesenteric arterioles of Wistar rats studied in vivo-in situ. Peptides 27, 1770-1775
31. Ferrario, C. M., Trask, A. J. and Jessup, J. A. (2005) Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function. Am. J. Physiol. Heart Circ. Physiol. 289, H2281-H2290
32. Benter, I. F., Ferrario, C. M., Morris, M. and Diz, D. I. (1995) Antihypertensive actions of angiotensin-(1-7) in spontaneously hypertensive rats. Am. J. Physiol. 269, H313-H319
33. Santos, R. A., Simoes e Silva, A. C., Maric, C., Silva, D. M., Machado, R. P., de Buhr, I., Heringer-Walther, S., Pinheiro, S. V., Lopes, M. T., Bader, M. et al. (2003) Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc. Natl. Acad. Sci. U.S.A. 100, 8258-8263
34. Ferreira, A. J., Santos, R. A. and Raizada, M. K. (2012) Angiotensin-(1-7)/angiotensin-converting enzyme 2/mas receptor axis and related mechanisms. Int. J. Hypertens. 2012, 690785
35. Acuna, M. J., Pessina, P., Olguin, H., Cabrera, D., Vio, C. P., Bader, M., Munoz-Canoves, P., Santos, R. A., Cabello-Verrugio, C. and Brandan, E. (2014) Restoration of muscle strength in dystrophic muscle by angiotensin-1-7 through inhibition of TGF-beta signalling. Hum. Mol. Genet. 23, 1237-1249
36. Sabharwal, R. and Chapleau, M. W. (2014) Autonomic, locomotor and cardiac abnormalities in a mouse model of muscular dystrophy: targeting the renin-angiotensin system. Exp. Physiol. 99, 627-631
37. Munoz, M. C., Giani, J. F., Burghi, V., Mayer, M. A., Carranza, A., Taira, C. A. and Dominici, F. P. (2012) The Mas receptor mediates modulation of insulin signaling by angiotensin-(1-7). Regul. Pept. 177, 1-11
38. Prasannarong, M., Santos, F. R. and Henriksen, E. J. (2012) ANG-(1-7) reduces ANG II-induced insulin resistance by enhancing Akt phosphorylation via a Mas receptor-dependent mechanism in rat skeletal muscle. Biochem. Biophys. Res. Commun. 426, 369-373
39. Echeverria-Rodriguez, O., Del Valle-Mondragon, L. and Hong, E. (2013) Angiotensin 1-7 improves insulin sensitivity by increasing skeletal muscle glucose uptake in vivo. Peptides 51, 26-30
40. Morales, M. G., Abrigo, J., Meneses, C., Simon, F., Cisternas, F., Rivera, J. C., Vazquez, Y. and Cabello-Verrugio, C. (2014) The Ang-(1-7)/Mas-1 axis attenuates the expression and signalling of TGF-beta1 induced by AngII in mouse skeletal muscle. Clin. Sci. 127, 251-264
41. Sabharwal, R., Cicha, M. Z., Sinisterra, R. D., De Sousa, F. B., Santos, R. A. and Chapleau, M. W. (2014) Chronic oral administration of Ang-(1-7) improves skeletal muscle, autonomic and locomotor phenotypes in muscular dystrophy. Clin. Sci. (Lond). 127, 101-109
42. Painemal, P., Acuna, M. J., Riquelme, C., Brandan, E. and Cabello-Verrugio, C. (2013) Transforming growth factor type beta 1 increases the expression of angiotensin II receptor type 2 by a SMAD- and p38 MAPK-dependent mechanism in skeletal muscle. Biofactors 39, 467-475
43. Morales, M. G., Vazquez, Y., Acuna, M. J., Rivera, J. C., Simon, F., Salas, J. D., Alvarez Ruf, J., Brandan, E. and Cabello-Verrugio, C. (2012) Angiotensin II-induced pro-fibrotic effects require p38MAPK activity and transforming growth factor beta 1 expression in skeletal muscle cells. Int. J. Biochem. Cell Biol. 44, 1993-2002
44. Riquelme, C., Acuna, M. J., Torrejon, J., Rebolledo, D., Cabrera, D., Santos, R. A. and Brandan, E. (2014) ACE2 is augmented in dystrophic skeletal muscle and plays a role in decreasing associated fibrosis. PLoS ONE 9, e93449
45. Meinen, S., Lin, S., Ruegg, M. A. and Punga, A. R. (2012) Fatigue and muscle atrophy in a mouse model of myasthenia gravis is paralleled by loss of sarcolemmal nNOS. PLoS ONE 7, e44148
46. Morales, M. G., Gutierrez, J., Cabello-Verrugio, C., Cabrera, D., Lipson, K. E., Goldschmeding, R. and Brandan, E. (2013) Reducing CTGF/CCN2 slows down mdx muscle dystrophy and improves cell therapy. Hum. Mol. Genet. 22, 4938-4951
47. Morales, M. G., Cabello-Verrugio, C., Santander, C., Cabrera, D., Goldschmeding, R. and Brandan, E. (2011) CTGF/CCN-2 over-expression can directly induce features of skeletal muscle dystrophy. J. Pathol. 225, 490-501
48. Morales, M. G., Cabrera, D., Cespedes, C., Vio, C. P., Vazquez, Y., Brandan, E. and Cabello-Verrugio, C. (2013) Inhibition of the angiotensin-converting enzyme decreases skeletal muscle fibrosis in dystrophic mice by a diminution in the expression and activity of connective tissue growth factor (CTGF/CCN-2). Cell Tissue Res. 353, 173-187
49. Deacon, R. M. (2013) Measuring the strength of mice. J. Vis. Exp. 2013, doi: 10.3791/2610
50. Lopez Verrilli, M. A., Pirola, C. J., Pascual, M. M., Dominici, F. P., Turyn, D. and Gironacci, M. M. (2009) Angiotensin-(1-7) through AT receptors mediates tyrosine hydroxylase degradation via the ubiquitin-proteasome pathway. J. Neurochem. 109, 326-335
51. Ohshima, K., Mogi, M., Nakaoka, H., Iwanami, J., Min, L. J., Kanno, H., Tsukuda, K., Chisaka, T., Bai, H. Y., Wang, X. L. et al. (2014) Possible role of angiotensin-converting enzyme 2 and activation of angiotensin II type 2 receptor by angiotensin-(1-7) in improvement of vascular remodeling by angiotensin II type 1 receptor blockade. Hypertension 63, e53-e59
52. Sampaio, W. O., Souza dos Santos, R. A., Faria-Silva, R., da Mata Machado, L. T., Schiffrin, E. L. and Touyz, R. M. (2007) Angiotensin-(1-7) through receptor Mas mediates endothelial nitric oxide synthase activation via Akt-dependent pathways. Hypertension 49, 185-192
53. Dias-Peixoto, M. F., Santos, R. A., Gomes, E. R., Alves, M. N., Almeida, P. W., Greco, L., Rosa, M., Fauler, B., Bader, M., Alenina, N. and Guatimosim, S. (2008) Molecular mechanisms involved in the angiotensin-(1-7)/Mas signaling pathway in cardiomyocytes. Hypertension 52, 542-548
54. Munoz, M. C., Giani, J. F. and Dominici, F. P. (2010) Angiotensin-(1-7) stimulates the phosphorylation of Akt in rat extracardiac tissues in vivo via receptor Mas. Regul. Pept. 161, 1-7
55. Cozzone, D., Frojdo, S., Disse, E., Debard, C., Laville, M., Pirola, L. and Vidal, H. (2008) Isoform-specific defects of insulin stimulation of Akt/protein kinase B (PKB) in skeletal muscle cells from type 2 diabetic patients. Diabetologia 51, 512-521
56. Zhang, L., Wang, X. H., Wang, H., Du, J. and Mitch, W. E. (2010) Satellite cell dysfunction and impaired IGF-1 signaling cause CKD-induced muscle atrophy. J. Am. Soc. Nephrol. 21, 419-427
57. Yoshida, T., Galvez, S., Tiwari, S., Rezk, B. M., Semprun-Prieto, L., Higashi, Y., Sukhanov, S., Yablonka-Reuveni, Z. and Delafontaine, P. (2013) Angiotensin II inhibits satellite cell proliferation and prevents skeletal muscle regeneration. J. Biol. Chem. 288, 23823-23832
58. Clarke, B. A., Drujan, D., Willis, M. S., Murphy, L. O., Corpina, R. A., Burova, E., Rakhilin, S. V., Stitt, T. N., Patterson, C., Latres, E. and Glass, D. J. (2007) The E3 Ligase MuRF1 degrades myosin heavy chain protein in dexamethasone-treated skeletal muscle. Cell Metab. 6, 376-385
59. Cohen, S., Brault, J. J., Gygi, S. P., Glass, D. J., Valenzuela, D. M., Gartner, C., Latres, E. and Goldberg, A. L. (2009) During muscle atrophy, thick, but not thin, filament components are degraded by MuRF1-dependent ubiquitylation. J. Cell Biol. 185, 1083-1095
60. Lokireddy, S., McFarlane, C., Ge, X., Zhang, H., Sze, S. K., Sharma, M. and Kambadur, R. (2011) Myostatin induces degradation of sarcomeric proteins through a Smad3 signaling mechanism during skeletal muscle wasting. Mol. Endocrinol. 25, 1936-1949
61. Lokireddy, S., Wijesoma, I. W., Sze, S. K., McFarlane, C., Kambadur, R. and Sharma, M. (2012) Identification of atrogin-1-targeted proteins during the myostatin-induced skeletal muscle wasting. Am. J. Physiol. Cell Physiol. 303, C512-C529
62. Lagirand-Cantaloube, J., Offner, N., Csibi, A., Leibovitch, M. P., Batonnet-Pichon, S., Tintignac, L. A., Segura, C. T. and Leibovitch, S. A. (2008) The initiation factor eIF3-f is a major target for atrogin1/MAFbx function in skeletal muscle atrophy. EMBO J. 27, 1266-1276
63. Lagirand-Cantaloube, J., Cornille, K., Csibi, A., Batonnet-Pichon, S., Leibovitch, M. P. and Leibovitch, S. A. (2009) Inhibition of atrogin-1/MAFbx mediated MyoD proteolysis prevents skeletal muscle atrophy in vivo. PLoS ONE 4, e4973
64. Kandarian, S. C. and Jackman, R. W. (2006) Intracellular signaling during skeletal muscle atrophy. Muscle Nerve 33, 155-165
65. Sandri, M., Sandri, C., Gilbert, A., Skurk, C., Calabria, E., Picard, A., Walsh, K., Schiaffino, S., Lecker, S. H. and Goldberg, A. L. (2004) Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 117, 399-412
66. Jackman, R. W. and Kandarian, S. C. (2004) The molecular basis of skeletal muscle atrophy. Am. J. Physiol. Cell Physiol. 287, C834-C843